Elsevier

Bone

Volume 134, May 2020, 115270
Bone

Correspondence
Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis

https://doi.org/10.1016/j.bone.2020.115270Get rights and content

Section snippets

Declaration of competing interest

None.

References (2)

Investigation performed at the Department of Orthopaedic Surgery, Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

1

These authors contributed equally to this work.

View full text